Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis
|
By LabMedica International staff writers Posted on 29 Apr 2016 |
Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
Latest Molecular Diagnostics News
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
- Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
- New Blood Test Aims to Transform Liver Cancer Surveillance
- New Biomarkers Indicate Higher Liver Cancer Risk in Chronic Hepatitis B Patients
- Precision Analyzer Reveals ‘Chameleon Proteins’ Causing Intractable Diseases
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








